Ajanta Pharmaceuticals

    AJANTPHARM
    Pharma
    ₹3,273.80
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹40,909 Cr

    P/E
    32.41
    Day range
    ₹3,268.00 – ₹3,340.00
    52-week range
    ₹2,446.80 – ₹3,796.00
    Volume
    86,171
    Open
    ₹3,300.00
    Prev close
    ₹3,312.50

    Latest results · Q2 FY27(consolidated)Revenue ₹1,794 Cr+32.5%Profit ₹388 Cr+49.2%Margin 21.6%YoY vs the same quarter last year

    1 red flag to read up on

    • medium

      Promoter holding falling

      63.47%, down 2.78 pts since 2025-09-30 · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 65 / 100

    Factor percentiles

    Value36
    Quality71
    Momentum56
    Low volatility96

    Derived metrics

    Earn. yield
    3.1%
    Graham no.
    ₹938.97
    vs Graham
    -71.3%
    ROE ÷ P/B
    3.0%
    12-1 mom.
    +31.6%
    Return / vol
    1.17
    Magic Formula
    #106
    Piotroski
    2/6
    FCF yield
    0.4%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Ajanta PharmaceuticalsAJANTPHARM₹40,909 Cr32.418.4425.4%35.0%31.0%0.03+32.5%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Key metrics

    P/E (TTM)
    32.4
    Price / Book
    8.42
    ROE (FY26)
    25.4%
    ROCE (latest year)
    35%
    Dividend yield
    0.98%

    Moving averages (NSE)

    20-day
    ₹3,340.93
    Price below
    50-day
    ₹3,430.75
    Price below
    200-day
    ₹3,200.35
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +13.4%
    Profit 3Y CAGR
    +21.6%
    Revenue YoY (Sep 2026)
    +32.5%
    Profit YoY (Sep 2026)
    +49.2%
    Operating margin
    31.0%
    Net margin
    21.6%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr500 Cr1K Cr1.5K Cr2K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%20%40%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • FII
    • Public
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-2K Cr-1K Cr0 Cr1K Cr2K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%40%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr2K Cr4K Cr6K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 22 Jun 2022: earlier bars are per pre-bonus share.

    FY19FY20FY21FY22FY23FY24FY25FY26FY27₹0₹10₹20₹30₹40

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales1,1051,0541,1451,1871,1461,1701,3031,3541,3751,4221,6261,794
    Expenses7917768158758258739511,0269931,0881,2021,247
    Operating Profit314278330311321297351328382333424548
    OPM %28%26%29%26%28%25%27%24%28%23%26%31%
    Other Income143626193018265925617137
    Interest221686535232
    Depreciation343434343640414344454448
    Profit before tax291278322290307269331341359347447535
    Tax %28%27%24%25%24%16%23%24%24%23%25%27%
    Net Profit210203246216233225255260274267334388
    EPS in Rs₹16.39₹15.82₹19.68₹17.33₹18.64₹18.03₹20.44₹20.83₹21.91₹21.35₹26.75₹31.06

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days124

    +31 days since Mar 2021

    Inventory Days289

    -145 days since Mar 2021

    Days Payable168

    -44 days since Mar 2021

    Cash Conversion Cycle246

    -69 days since Mar 2021

    Working Capital Days111

    -15 days since Mar 2021

    Strengths, risks & growth

    Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).

    Strengths

    • Company is almost debt free.
    • Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%
    • Company has been maintaining a healthy dividend payout of 50.1%

    Risks

    • Stock is trading at 8.42 times its book value

    Compounded Sales Growth

    10 Years
    +12%
    5 Years
    +14%
    3 Years
    +13%
    TTM
    +25%

    Compounded Profit Growth

    10 Years
    +10%
    5 Years
    +12%
    3 Years
    +24%
    TTM
    +30%

    Stock Price CAGR

    10 Years
    +11%
    5 Years
    +18%
    3 Years
    +18%
    1 Year
    +30%

    Return on Equity

    10 Years
    +23%
    5 Years
    +23%
    3 Years
    +25%
    Last Year
    +27%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter66.25%66.25%63.49%63.47%-0.02 pp
    FII7.97%8.26%7.68%7.62%-0.06 pp
    DII18.58%18.36%21.80%21.94%+0.14 pp
    Government0.01%0.01%0.00%0.00%0.00 pp
    Public7.20%7.14%7.03%6.96%-0.07 pp

    Filed with NSE for Sept 2026: promoters 63.47%, public 36.53%

    Analysts & fund holdings

    75%
    75% recommend buy
    12 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E32.4 vs 45.2
    Sector P/B6.05
    Beta0.55

    Who holds the shares, quarter by quarter

    Mutual funds 17.95% (-0.15 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters63.5%
    • Foreign institutions7.6%
    • Mutual funds17.9%
    • Insurance3.6%
    • Other domestic institutions0.4%
    • Retail5.6%
    • Others1.4%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Nippon India Small Cap Fund1.40%0.76%+0.03 pp
    Kotak Flexi Cap Fund1.35%1.08%+0.08 pp
    UTI Flexi Cap Fund1.08%2.03%+0.11 pp
    Kotak Small Cap Fund0.97%2.13%+0.03 pp
    Kotak Large & Mid Cap Fund0.82%1.12%+0.06 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    25.2%
    Downside volatility
    22.4%
    Worst 5% of days
    2.5%
    Average of that tail
    3.0%
    Max drawdown (1Y)
    13.2%
    Below its peak
    12.0%

    Against the market

    Beta vs Nifty 50
    0.46
    Correlation
    0.24
    Relative strength (3M)
    -15.8%
    ATR (14)
    3.2%

    Return

    Return 1M
    -1.7%
    Return 3M
    -12.0%
    Return 6M
    +1.9%
    Return 1Y
    +29.5%
    vs 200-day average
    +2.3%

    Momentum

    RSI (14)
    42.0
    MACD histogram
    -0.22
    Stochastic %K
    5.9
    ADX (14)
    11.0
    +DI / −DI
    19.3 / 17.9
    Money flow index
    45.5

    Participation

    Delivery (20d avg)
    55.0%
    vs its 60-day baseline
    +0.6 pts
    Volume vs 20-day
    -0.5σ
    Close vs day's VWAP
    -0.7%
    52-week position
    67 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    2 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — failed
    Free cash flow
    ₹164 Cr
    FCF yield
    0.4%
    Cash conversion
    0.50
    Accruals ratio
    0.086
    Net debt
    ₹64 Cr
    Net debt / equity
    0.01
    EV / sales
    6.59
    Capex intensity
    6.7%
    Revenue CAGR
    32.9%
    Profit CAGR
    43.7%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net selling ₹39.2 L
    0 buys · ₹0
    2 sells · ₹39.2 L
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    SHAILESH R SINGH
    Other · Market Sale
    Sell607₹18.8 L13 Mar 2026
    SHAILESH R SINGH
    Other · Market Sale
    Sell750₹20.3 L29 Dec 2025
    SHAILESH R SINGH
    Other · Market Sale
    Sell3,000₹75.9 L13 Nov 2025
    SHAILESH R SINGH
    Other · Market Sale
    Sell2,000₹51.3 L13 Nov 2025

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹32.00

      Interim Dividend - Rs 32 Per Share

      5 Aug 2026
      ex-date
    • dividend
      ₹28.00

      Interim Dividend - Rs 28 Per Share

      10 Nov 2025
      ex-date
    • dividend
      ₹28.00

      Interim Dividend - Rs 28 Per Share

      6 Nov 2024
      ex-date
    • buyback
      Not available — not reported in this filing

      Buy Back

      30 May 2024
      ex-date
    • dividend
      ₹26.00

      Interim Dividend - Rs 26 Per Share

      8 Feb 2024
      ex-date
    • dividend
      ₹10.00

      Interim Dividend - Rs 10 Per Share/Special Dividend - Rs 15 Per Share

      4 Aug 2023
      ex-date
    • buyback
      Not available — not reported in this filing

      Buy Back

      24 Mar 2023
      ex-date
    • dividend
      ₹7.00

      Interim Dividend - Rs 7 Per Share

      11 Nov 2022
      ex-date
    • bonus
      Not available — not reported in this filing

      Bonus- 1:2

      22 Jun 2022
      ex-date
    • buyback
      Not available — not reported in this filing

      Buyback

      13 Jan 2022
      ex-date
    • dividend
      ₹9.50

      Interim Dividend - Rs 9.50 Per Share

      9 Nov 2021
      ex-date
    • buyback
      Not available — not reported in this filing

      Buyback

      12 Nov 2020
      ex-date
    • dividend
      ₹9.50

      Interim Dividend - Rs 9.50 Per Share

      12 Nov 2020
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      21 Jul 2020
      ex-date
    • dividend
      ₹13.00

      Interim Dividend - Rs 13 Per Share

      15 Nov 2019
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      9 Jul 2019
      ex-date
    • buyback
      Not available — not reported in this filing

      Buy Back

      11 Feb 2019
      ex-date
    • dividend
      ₹9.00

      Interim Dividend - Rs 9 Per Sh

      9 Nov 2018
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      26 Jun 2018
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      23 Jun 2017
      ex-date

    Company announcements

    Insider Trading / SAST
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CTL Trusteeship Ltd

    Company Update
    Submission Of Sustainability Report For FY 2026

    Pls find enclosed herewith Sustainability Report for FY 2026.

    Insider Trading / SAST
    Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

    The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 28, 2026 for Aayush Agrawal, ....

    Insider Trading / SAST
    Closure of Trading Window

    Pls find enclosed herewith closure of trading window intimation

    Insider Trading / SAST
    Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

    The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 18, 2026 for Aayush Agrawal, ....

    Company Update
    Participation In Investor Conference

    Pls find enclosed Intimation w.r.t Participation in Investor Conference.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Pls find enclosed newspaper publication for transfer of equity shares to IEPF.

    Insider Trading / SAST
    Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 27, 2026 for Aayush Agrawal, trustee ....

    Insider Trading / SAST
    Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

    The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 19, 2026 for Ravi Agrawal, trustee ....

    Insider Trading / SAST
    Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

    The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 14, 2026 for Ravi Agrawal, trustee ....

    Company Update
    Participation In Investor Conference

    Pls find enclosed Intimation w.r.t participation in Investor Conference

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Pls find enclosed herewith Earning Call Transcript

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Pls find enclosed newspaper publication of financial results for the quarter ended 30.06.2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Pls find enclosed Audio Recording of Earnings Call

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    Pls find enclosed ESOP Allotment

    Filed with BSE (scrip 532331); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 30 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Ajanta Pharmaceuticals: common questions

    Answered from the figures on this page.

    Ajanta Pharmaceuticals last traded at ₹3,273.80 (NSE, as of 18 Nov 2026). The last session moved it down 1.17%.

    Ajanta Pharmaceuticals is valued at about ₹40,909 crore (NSE, as of 18 Nov 2026).

    Ajanta Pharmaceuticals trades at a price-to-earnings ratio of 32.41 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Ajanta Pharmaceuticals has traded between ₹2,446.80 and ₹3,796.00 over the past 52 weeks, to 18 Nov 2026. It is currently 61% of the way up that range.

    Ajanta Pharmaceuticals (AJANTPHARM) is classified under Pharma on this site's screener.